ArticleDiagnostics (Basel, Switzerland)2021
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.Nature reviews. Gastroenterology & hepatology · 2023Guideline
- Trial
- Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.Current pharmaceutical design · 2026Review
- Prognostic Role of Circulating DNA in Biliary Tract Cancers: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- LINE-1 hypomethylation in cell-free DNA of high-grade glioma patients correlates with tissue levels and is associated with reduced DNMT1 and H4K20me3 expression.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- The bile duct and liver cancer: ON-treatment surveillance of tumor evolution and response to systemic treatment (BILLIONSTARS) study.BMC cancer · 2025Observational
- Review
- Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy.Cancers · 2025Review
- Circulating tumor DNA in management of primary liver malignancy: A review of the literature and future directions.Journal of surgical oncology · 2025Review
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.The American journal of pathology · 2025Review
- Diagnostic accuracy of cfDNA levels in gallbladder cancer: A study using qPCR & threshold evaluation.The Indian journal of medical research · 2025Article
- Bile-Derived cfDNA of Syncytin-1 and SLC7A11 as a Potential Molecular Marker for Early Diagnosis of Cholangiocarcinoma.Journal of gastrointestinal cancer · 2025Article
- Liquid biopsy in biliary tract cancers: early diagnosis, precision therapy, and prognostic evaluation.Frontiers in oncology · 2025Review
- Article
- Practice guidelines for managing extrahepatic biliary tract cancers.Annals of hepato-biliary-pancreatic surgery · 2024Article
- Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.Journal of experimental & clinical cancer research : CR · 2024Article
- Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.Cancers · 2024Review
- Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.JCO precision oncology · 2024Article
- Cell-free DNA as a prognostic and predictive biomarker in resectable distal common bile duct cancer.Journal of the Chinese Medical Association : JCMA · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The analysis of cfDNA has been applied as a liquid biopsy in several malignancies. However, its value in the diagnosis and prognosis of cholangiocarcinoma (CCA) have not been well defined. We aimed to investigate the diagnostic and prognostic values of cfDNA level and tumor-specific mutation in circulating DNA (ctDNA) in CCA. The plasma cfDNA levels from 62 CCA patients, 33 benign biliary disease (BBD) patients and 30 normal controls were quantified by fluorescent assay. Targeted probe-based sequencing of 60 genes was applied for mutation profiling in 10 ctDNA samples and their corresponding treatment-naïve tissues. cfDNA levels in CCA were significantly higher than those in BBD and normal controls. We found that cfDNA levels at 0.2175 and 0.3388 ng/µL significantly discriminated CCA from healthy controls and BBD with 88.7 and 82.3% sensitivity and 96.7 and 57.6% specificity, respectively. cfDNA levels showed superior diagnostic efficacy in detecting CCA compared to CEA and CA19-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.